EYE — Nova Eye Medical Cashflow Statement
0.000.00%
- AU$44.04m
- AU$42.00m
- AU$29.27m
- 47
- 53
- 84
- 68
Annual cashflow statement for Nova Eye Medical, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 0.027 | 0.041 | 0.489 | 0.511 | 0 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | -13.1 | -4.72 | -6.82 | -7.86 | -6.15 |
Capital Expenditures | -0.809 | -3.72 | -0.567 | -0.449 | -0.426 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -2.17 | -0.819 | -0.13 | 0.124 | 0.062 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -2.98 | -4.54 | -0.697 | -0.325 | -0.364 |
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -61.6 | -0.402 | 6.82 | 6.91 | 5.56 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -77.8 | -9.8 | -0.581 | -1.27 | -1.1 |